Ethical review of off-label drugs during the COVID-19 pandemic
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved..
High-quality scientific research is very important in attempting to effectively control the coronavirus disease 2019 (COVID-19) pandemic and ensure people's health and safety. Chloroquine (CQ) and hydroxychloroquine (HCQ) have received much attention. This article comprehensively investigates the ethical review of off-label CQ and HCQ research during the COVID-19 pandemic with regard to strictly abiding by review standards, improving review efficiency, ensuring the rights and interests of subjects and that ethics committees conduct independent reviews, and achieving full ethics supervision of research conducted during an emergency. Research must be both rigorous and prudent to ensure the best outcome, with the maximization of benefits as the core principle. Standardization of the application, implementation and ethical review processes are needed to prevent unnecessary risk.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
World journal of clinical cases - 10(2022), 17 vom: 16. Juni, Seite 5541-5550 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Qiu-Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 19.08.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.12998/wjcc.v10.i17.5541 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344977226 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344977226 | ||
| 003 | DE-627 | ||
| 005 | 20231226024016.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12998/wjcc.v10.i17.5541 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344977226 | ||
| 035 | |a (NLM)35979109 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Qiu-Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ethical review of off-label drugs during the COVID-19 pandemic |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a High-quality scientific research is very important in attempting to effectively control the coronavirus disease 2019 (COVID-19) pandemic and ensure people's health and safety. Chloroquine (CQ) and hydroxychloroquine (HCQ) have received much attention. This article comprehensively investigates the ethical review of off-label CQ and HCQ research during the COVID-19 pandemic with regard to strictly abiding by review standards, improving review efficiency, ensuring the rights and interests of subjects and that ethics committees conduct independent reviews, and achieving full ethics supervision of research conducted during an emergency. Research must be both rigorous and prudent to ensure the best outcome, with the maximization of benefits as the core principle. Standardization of the application, implementation and ethical review processes are needed to prevent unnecessary risk | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Chloroquine | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a Off-label | |
| 700 | 1 | |a Lv, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a An, Zhuo-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Ni-Ni |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Li-Jun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of clinical cases |d 2013 |g 10(2022), 17 vom: 16. Juni, Seite 5541-5550 |w (DE-627)NLM233331727 |x 2307-8960 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:17 |g day:16 |g month:06 |g pages:5541-5550 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12998/wjcc.v10.i17.5541 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 17 |b 16 |c 06 |h 5541-5550 | ||